Skip to main content
Denali Therapeutics Inc. logo

Denali Therapeutics Inc. — Investor Relations & Filings

Ticker · DNLI ISIN · US24823R1059 LEI · 549300ZTQ2HO18L3Q830 US Manufacturing
Open in API
Filings indexed 749 across all filing types
Latest filing 2023-04-15 Director's Dealing
Country US United States of America
Listing US DNLI

About Denali Therapeutics Inc.

https://www.denalitherapeutics.com

Denali Therapeutics Inc. is a biopharmaceutical company dedicated to discovering and developing therapies for neurodegenerative diseases, lysosomal storage disorders, and other serious illnesses. The company's core scientific strategy centers on its proprietary Transport Vehicle™ (TV) platform, which is engineered to transport large therapeutic molecules, such as antibodies and enzymes, across the blood-brain barrier. This technology is designed to overcome a primary obstacle in treating diseases of the central nervous system. Denali's pipeline comprises a portfolio of investigational drug candidates that leverage this platform to target the underlying genetic and biological pathways of complex diseases.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2023-04-15 English
SC 13G
Major Shareholding Notification
2023-03-30 English
S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by Denali Therapeutics Inc. It is a registration statement under the Securities Act of 1933 for securities to be offered under employee benefit plans (2017 Equity Incentive Plan and 2017 Employee Stock Purchase Plan). The document includes legal and regulatory disclosures, indemnification provisions, incorporation by reference of prior filings (including the 10-K), and exhibits. It is not a financial report, earnings release, or management discussion. It is a regulatory filing related to securities registration, not a report or announcement of financial results or corporate governance changes. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2023-02-27 English
10-K
Annual Report FY 2022
2023-02-27 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 27, 2023, by Denali Therapeutics Inc. It announces the issuance of a press release with financial results for the fourth quarter ended December 31, 2022. The text states that the press release is attached as Exhibit 99.1 and incorporated by reference, but the document itself does not contain detailed financial statements or substantive financial data. The length is 3499 characters, which is relatively short and consistent with an announcement rather than a full earnings release. According to the 'Menu vs Meal' rule, this is an announcement of a report (the press release) rather than the report itself. Therefore, the appropriate classification is Earnings Release (ER), as the document announces quarterly financial results and includes the press release text as an exhibit. Confidence is high because the document explicitly states it is announcing financial results for a quarter and includes a press release with those results.
2023-02-27 English
FORM 4
Director's Dealing
2023-02-17 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.